Table 2.

Immunological outcome following combination antiretroviral therapy according to the rapid progressors status from linear mixed-effects model in the univariate and multivariate analyses.

Months from cART initiation			Unadjusted analyses		Adjusted analyses
					Model 1a		Model 1 + postestimation adjustment procedureb
	Mean (95% CI) increase in CD4+ T-cell count per month (square root scale)		Difference (95% CI) in mean increase in CD4+ T-cell count per month (square root scale)	P value	Difference (95% CI) in mean increase in CD4+ T-cell count per month (square root scale)	P value	Difference (95% CI) in mean increase in CD4+ T-cell count per month (square root scale)	P value
	Nonrapid progressors	Rapid progressors	Rapid vs. nonrapid progressors
0–1	2.94 (2.84; 3.05)	4.55 (4.17; 4.92)	1.60 (1.21; 1.99)	<0.001	1.34 (0.95; 1.72)	<0.001	1.82 (1.61; 2.04)	<0.001
1–18	0.17 (0.16; 0.17)	0.20 (0.17; 0.22)	0.03 (0.004; 0.06)	0.024	0.03 (−0.001; 0.05)	0.063	−0.05 (−0.06; −0.03)	<0.001
18–60	0.04 (0.03; 0.04)	0.07 (0.06; 0.09)	0.04 (0.02; 0.05)	<0.001	0.04 (0.02; 0.06)	<0.001	−0.003 (−0.01; 0.01)	0.62

CI, confidence interval; cART, combination antiretroviral therapy.

^aFrom an initial piecewise linear mixed model including rapid progressors status, sex, age at cART initiation, risk group (MSM, sex between men and women, IDUs), geographical origin (migrants from sub-Saharan Africa, non-sub-Saharan Africa, unknown) used as a proxy of subtype and log₁₀ HIV-RNA levels at cART initiation.

^bAfter the postestimation adjustment procedure to provide an estimate of the difference for patients with the same underlying CD4⁺ T-cell count at cART initiation.